BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33589921)

  • 1. Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
    Craig JM; Turner TH; Harrell JC; Clevenger CV
    Endocrinology; 2021 May; 162(5):. PubMed ID: 33589921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
    Medler TR; Craig JM; Fiorillo AA; Feeney YB; Harrell JC; Clevenger CV
    Mol Cancer Res; 2016 Oct; 14(10):994-1008. PubMed ID: 27358110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.
    Fiorillo AA; Medler TR; Feeney YB; Liu Y; Tommerdahl KL; Clevenger CV
    Mol Endocrinol; 2011 Sep; 25(9):1550-64. PubMed ID: 21816901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
    Tran TH; Utama FE; Lin J; Yang N; Sjolund AB; Ryder A; Johnson KJ; Neilson LM; Liu C; Brill KL; Rosenberg AL; Witkiewicz AK; Rui H
    Cancer Res; 2010 Feb; 70(4):1711-21. PubMed ID: 20124477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.
    Fang F; Rycyzyn MA; Clevenger CV
    Endocrinology; 2009 Apr; 150(4):1597-606. PubMed ID: 19036881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.
    Schauwecker SM; Kim JJ; Licht JD; Clevenger CV
    J Biol Chem; 2017 Feb; 292(6):2237-2254. PubMed ID: 28035005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells.
    Linher-Melville K; Singh G
    BMC Cancer; 2014 Jun; 14():415. PubMed ID: 24913037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer.
    Woock AE; Grible JM; Olex AL; Harrell JC; Zot P; Idowu M; Clevenger CV
    Sci Rep; 2021 Jun; 11(1):13506. PubMed ID: 34188118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT5A is regulated by DNA damage via the tumor suppressor p53.
    Mukhopadhyay UK; Cass J; Raptis L; Craig AW; Bourdeau V; Varma S; SenGupta S; Elliott BE; Ferbeyre G
    Cytokine; 2016 Jun; 82():70-9. PubMed ID: 26876578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
    Subtil-Rodríguez A; Millán-Ariño L; Quiles I; Ballaré C; Beato M; Jordan A
    Mol Cell Biol; 2008 Jun; 28(11):3830-49. PubMed ID: 18378698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.
    Yang X; Meyer K; Friedl A
    J Biol Chem; 2013 Jul; 288(29):21184-21196. PubMed ID: 23729680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.
    Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
    Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5 Regulation of Sex-Dependent Hepatic CpG Methylation at Distal Regulatory Elements Mapping to Sex-Biased Genes.
    Hao P; Waxman DJ
    Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33199496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
    Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
    Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells.
    Duan R; Ginsburg E; Vonderhaar BK
    Mol Cell Endocrinol; 2008 Jan; 281(1-2):9-18. PubMed ID: 18022314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.
    Verdier F; Rabionet R; Gouilleux F; Beisenherz-Huss C; Varlet P; Muller O; Mayeux P; Lacombe C; Gisselbrecht S; Chretien S
    Mol Cell Biol; 1998 Oct; 18(10):5852-60. PubMed ID: 9742102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
    Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ
    Nat Commun; 2020 Jan; 11(1):320. PubMed ID: 31949157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.
    Carsol JL; Gingras S; Simard J
    Mol Endocrinol; 2002 Jul; 16(7):1696-710. PubMed ID: 12089361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.